Journal article · 2024 · Open access

GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy

Daniel Terheyden-Keighley, Melanie Hühne, Thomas G. Berger, Björn Hiller, Soraia Martins, Anna Gamerschlag, Davood Sabour, Andrea Meffert, Andreas Kislat, Carsten Slotta, François Hafezi, Jens Lichte and 6 more

Stem Cells Translational Medicine, 13(9), 898–911 · Published 23 July 2024 · DOI 10.1093/stcltm/szae047

Open full textCite this paper

In brief

“GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy” is a 2024 journal article by Daniel Terheyden-Keighley and 17 co-authors, published in Stem Cells Translational Medicine. OpenAlex counts 24 citations as of 21 November 2026, which puts it in the top 8% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Stem Cells Translational Medicine.

Citations
24
Most cited in
2026 (16)
Field-weighted impact
2.33
References
33
Authors
18

Abstract

Cell therapeutic applications based on induced pluripotent stem cells (iPSCs) appear highly promising and challenging at the same time. Good manufacturing practice (GMP) regulations impose necessary yet demanding requirements for quality and consistency when manufacturing iPSCs and their differentiated progeny. Given the scarcity of accessible GMP iPSC lines, we have established a corresponding production workflow to generate the first set of compliant cell banks. Hence, these lines met a comprehensive set of release specifications and, for instance, displayed a low overall mutation load reflecting their neonatal origin, cord blood. Based on these iPSC lines, we have furthermore developed a set of GMP-compatible workflows enabling improved gene targeting at strongly enhanced efficiencies and directed differentiation into critical cell types: A new protocol for the generation of retinal pigment epithelium (RPE) features a high degree of simplicity and efficiency. Mesenchymal stromal cells (MSCs) derived from iPSCs displayed outstanding expansion capacity. A fully optimized cardiomyocyte differentiation protocol was characterized by a particularly high batch-to-batch consistency at purities above 95%. Finally, we introduce a universal immune cell induction platform that converts iPSCs into multipotent precursor cells. These hematopoietic precursors could selectively be stimulated to become macrophages, T cells, or natural killer (NK) cells. A switch in culture conditions upon NK-cell differentiation induced a several thousand-fold expansion, which opens up perspectives for upscaling this key cell type in a feeder cell-independent approach. Taken together, these cell lines and improved manipulation platforms will have broad utility in cell therapy as well as in basic research.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Terheyden-Keighley, D., Hühne, M., Berger, T. G., Hiller, B., Martins, S., Gamerschlag, A., Sabour, D., Meffert, A., Kislat, A., Slotta, C., Hafezi, F., Lichte, J., Sudheer, S., Tessmer, K., Psathaki, K., Ader, M., Kögler, G., & Greber, B. (2024). GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy. Stem Cells Translational Medicine, 13(9), 898–911. https://doi.org/10.1093/stcltm/szae047

MLA 9

Terheyden-Keighley, Daniel, et al. “GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy.” Stem Cells Translational Medicine, vol. 13, no. 9, 2024, pp. 898–911. https://doi.org/10.1093/stcltm/szae047.

Chicago

Terheyden-Keighley, Daniel, Melanie Hühne, Thomas G. Berger, Björn Hiller, Soraia Martins, Anna Gamerschlag, Davood Sabour, et al. 2024. “GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy.” Stem Cells Translational Medicine 13 (9): 898–911. https://doi.org/10.1093/stcltm/szae047.

Harvard

Terheyden-Keighley, D. et al. (2024) ‘GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy’, Stem Cells Translational Medicine, 13(9), pp. 898–911. doi:10.1093/stcltm/szae047.

IEEE

D. Terheyden-Keighley et al., “GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy,” Stem Cells Translational Medicine, vol. 13, no. 9, pp. 898–911, 2024, doi: 10.1093/stcltm/szae047.

BibTeX

@article{terheydenkeighley2024compliant,
  title     = {{GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy}},
  author    = {Terheyden-Keighley, Daniel and Hühne, Melanie and Berger, Thomas G. and Hiller, Björn and Martins, Soraia and Gamerschlag, Anna and Sabour, Davood and Meffert, Andrea and Kislat, Andreas and Slotta, Carsten and Hafezi, François and Lichte, Jens and Sudheer, Smita and Tessmer, Karen and Psathaki, Katherina and Ader, Marius and Kögler, Gesine and Greber, Boris},
  journal   = {Stem Cells Translational Medicine},
  year      = {2024},
  volume    = {13},
  number    = {9},
  pages     = {898--911},
  doi       = {10.1093/stcltm/szae047},
  url       = {https://doi.org/10.1093/stcltm/szae047}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202422
202566
20261616

Its field-weighted citation impact is 2.33: it has been cited 2.33 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • induced pluripotent stem cells
  • GMP compliance
  • cell therapy manufacturing
  • cell banks
  • retinal pigment epithelium differentiation
  • mesenchymal stem cells
  • cardiomyocyte differentiation
  • hematopoietic precursors

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Terheyden-Keighley, D., Hühne, M., Berger, T. G., Hiller, B., Martins, S., Gamerschlag, A., Sabour, D., Meffert, A., Kislat, A., Slotta, C., Hafezi, F., Lichte, J., Sudheer, S., Tessmer, K., Psathaki, K., Ader, M., Kögler, G., & Greber, B. (2024). GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy. Stem Cells Translational Medicine, 13(9), 898–911. https://doi.org/10.1093/stcltm/szae047

How many times has this paper been cited?

24 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Stem Cells Translational Medicine: sign in and open the full text from this page.

Who wrote this paper?

Daniel Terheyden-Keighley, Melanie Hühne, Thomas G. Berger, Björn Hiller, Soraia Martins, Anna Gamerschlag, Davood Sabour, Andrea Meffert, Andreas Kislat, Carsten Slotta, François Hafezi, Jens Lichte and 6 more.

What is the DOI of this paper?

10.1093/stcltm/szae047, permanently at https://doi.org/10.1093/stcltm/szae047. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.